GlaxoSmithKline provided further evidence on Wednesday that its turnaround strategy is delivering the goods with the release of bubbly financials for the first half of 2016.
The medicines manufacturer saw total core turnover gallop 11% higher between January and June, it advised, to £12.8bn. And core in the second quarter grew by the same percentage, to £6.5bn.
